Table 2. Modification of R1 over Compound 11k.
compd | R1 | Cavα2δ-1 (Ki, nM)a | CYP3A4 inhibition (%)b |
---|---|---|---|
11m | 6-Br | 16 ± 28 | 95 |
11mR | 6-Br | 8 ± 2 | 94 |
11mS | 6-Br | 2903 ± 703 | 88 |
11n | 6-CN | 288 ± 139 | 70 |
11o | 6-NHEt | 44 ± 23 | 69 |
11p | 6-(4-pyridinyl) | 38 ± 13 | 92 |
11q | 7-Br | 15 ± 24 | 97 |
11r | 7-(4-pyridinyl) | 18 ± 24 | 97 |
11s | 5-Br | 66 ± 16 | 95 |
11t | 8-Br | >1000c | NDd |
Binding affinity (Ki, nM) in human α2δ-1 enriched membranes from hamster tumor CHO-K1 cells (Human Cav2.2/β3/α2δ1 Calcium Channel Cell Line, ChanTest) using [3H]-gabapentin as the radioligand. Each value is the mean ± SD of two determinations.
Percentage of inhibition after incubation at 1 μM with recombinant human CYP3A4 using BFC (7-benzyloxy-4-trifluoromethylcoumarin) as the CYP probe substrate and fluorescence detection.
Less than 50% inhibition at 1 μM.
Not determined.